Editorials

• Is device-based prevention of heart failure decompensation rising like a phoenix from the ashes?

  Paweł Krzesiński

  Rev Esp Cardiol. 2022;75:701-3

• No-reflow phenomenon in STEMI: beyond a good angiographic result

  Rafael Cobas Paz, Berenice Caneiro Queija, Andrés Íñiguez Romo

  Rev Esp Cardiol. 2022;75:706-8

• Diagnostic and therapeutic potential of miRNAs in cardiovascular disease: a clinical reality?

  Raquel López-Gálvez, Vanessa Roldán, Francisco Marín

  Rev Esp Cardiol. 2022;75:704-5

• Hemodynamic optimization in patients with a long-term ventricular assist device. A diagnostic and therapeutic challenge

  Aitor Uribarri

  Rev Esp Cardiol. 2022;75:618-20

• Plasma acylcarnitine, risk for heart failure or atrial fibrillation, and effects of the Mediterranean diet or obesity

  Annamaria Del Franco, Paolo Morfino, Alberto Aimo

  Rev Esp Cardiol. 2022;75:621-2

• Drug-eluting stents and contemporary dual antiplatelet therapy in revascularized STEMI. The times they are a-changin’?

  Luis M. Rincón, Eduardo Villacorta, Pedro L. Sánchez

  Rev Esp Cardiol. 2022;75:623-5

• Marfan syndrome and pregnancy-related aortic complications: contemporary outcomes from two Spanish Marfan units

  Beatriz Aldara Fernandez Campos, Candice K. Silversides

  Rev Esp Cardiol. 2022;75:542-4

• New 2021 ESC/HFA heart failure guidelines. A practical comprehensive approach

  Nicolás Manito

  Rev Esp Cardiol. 2022;75:548-51

• Programmed electrophysiological stimulation for risk prediction in patients with Brugada syndrome: closing time?

  Andrea Mazzanti, Alessandro Trancuccio, Silvia G. Priori

  Rev Esp Cardiol. 2022;75:545-7

• Go with the flow: physiological assessment of coronary artery stenosis severity in patients with severe aortic stenosis

  Tobias Rheude, Costanza Pellegrini, Michael Joner

  Rev Esp Cardiol. 2022;75:456-7

• Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure

  SEC Working Group for the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and SEC Guidelines Committee

  Rev Esp Cardiol. 2022;75:458-65

• Comments on the 2021 ESC/EACTS guidelines for the management of valvular heart disease

  SEC Working Group for the 2021 ESC/EACTS guidelines for the management of valvular heart disease and SEC Guidelines Committee

  Rev Esp Cardiol. 2022;75:466-71

• Confirming the validity of the ARC-HBR criteria in patients presenting with ACS: the first step in reducing bleeding risk

  Róisín Colleran, Philip Urban

  Rev Esp Cardiol. 2022;75:360-3

• Comments on the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy

  SEC Working Group for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy and the SEC Guidelines Committee

  Rev Esp Cardiol. 2022;75:370-4

• Comments on the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice

  SEC Working Group for the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice and SEC Guidelines Committee

  Rev Esp Cardiol. 2022;75:364-9

• Reduced survival of young people with aortic stenosis after valve replacement

  Laura Galian-Gay, Artur Evangelista

  Rev Esp Cardiol. 2022;75:286-7

• Use of primary care electronic medical records for research purposes: is it taking off?

  Gloria Santos-Beneit, Valentín Fuster, Rodrigo Fernández-Jiménez

  Rev Esp Cardiol. 2022;75:288-90

• The Codi IAM registry: acute myocardial infarction code registry in Catalonia

  Maria Teresa Faixedas, Josepa Mauri, Maria J. Pueyo, on behalf of the members of the Pla director de malalties cardiovasculares

  Rev Esp Cardiol. 2022;75:291-3

• Predicting neocommissural orientation during TAVI workup

  Marco Barbanti, Roberto Valvo, Giuliano Costa

  Rev Esp Cardiol. 2022;75:194-5

• The calcium pandemic and use of plaque modification devices in chronic total occlusion percutaneous coronary intervention

  Francesco Moroni, Lorenzo Azzalini

  Rev Esp Cardiol. 2022;75:196-9